Overview

Epilepsy is a disorder of the brain that causes repeated, unpredictable seizures, generally beginning in childhood or early adulthood. This condition can lead to serious complications, including injury to the brain.  Epilepsy means the brain has formed abnormal electrical connections that disrupt normal brain function and cause seizures. It can be caused by genetics or an injury, infection or illness to the brain, such as a stroke or brain tumor. Epilepsy can be caused by unknown reasons which occur in around half of cases.

Treatment options

In adults, medication can frequently control epilepsy. However, if seizures persist after trying two drugs, our expert neurosurgeons may offer epilepsy surgery. Surgical treatment may be considered if your seizures continue after trying two different medications.  Your neurosurgeon offers a diagnostic surgery for detection of difficult to localize seizures, also called intracranial EEG monitoring – this is to localize the seizure area and to map brain function. 

Surgical Procedures


A craniotomy is performed and sterile EEG leads are placed directly on the brain. The bone flap is placed back on the patient and secured.  The wound is then closed with the tails of the EEG leads coming out through the wound. These leads are connected to EEG monitors that are available in special rooms in the hospital. The patient is then monitored continuously for several days for seizure activity.  

There are several types of treatment surgery for adults:

  • Craniotomy, resection of seizure focus (removing abnormal brain areas) is considered if:
    • Your seizures are continuing after trying two different medications.
    • Your seizures arise from one site in the brain.
    • The site of the seizures has been pinpointed.
    • The removal of the portion of the brain causing the seizures will not impair your ability to function.
  • Vagus nerve stimulation (placing an implant in the neck to help prevent seizures)
  • Corpus callostomy (disrupting connections between the two sides of the brain)

 

Care team

Profiles

Jayant Acharya, MD

Neurologist and Epilepsy Specialist Neurology | Epilepsy
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Whitney Ringer, FNP-BC

Neurology Nurse Practitioner Neurology
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Mehul Trivedi, PhD

Clinical Psychologist Psychiatry
319 E Madison St 3rd Floor Springfield, IL 62702
Profiles

Dale Korinek, Psy.D

Clinical Neuropsychologist Psychiatry
319 E Madison St 3rd Floor Springfield, IL 62702
Profiles

Hossam AbdelSalam, MD

Pediatric Neurologist Neurology | Pediatrics
400 N. 9th Street Springfield, IL 62702
Profiles

Faisal Ibrahim, MD

Neurologist Neurology | Epilepsy
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Nitin Patel, MD

Pediatric Neurologist Neurology | Pediatrics
400 N. 9th Street Springfield, IL 62702
Profiles

Jose Espinosa, MD

Neurosurgeon Neurosurgery
747 N. Rutledge Street 2nd floor Springfield, IL 62702
Profiles

Alessandra Mantovani, MD

Neurosurgeon Neurosurgery
747 N. Rutledge Street 2nd floor Springfield, IL 62702
Profiles

Sajjad Mueed, MD

Director, Memorial Medical Center Stroke Center Neurology
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Jacob Monsivais, PA-C

Certified Physician Assistant Neurology
751 N. Rutledge St. Suite 3100 Springfield, IL 62702

 

Care facilities

Locations
Locations
Locations
Locations

 

Clinical trials

Trial
Neurology

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

Trial
Neurology

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

Trial
Neurology

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Trial
Neurology

Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.

Trial
Trial
Neurology

UCB EP0162: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting
The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.
Trial
Neurology

Xenon XPF-010-302: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting
The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.
Trial
Neurology

Xenon XPF-010-303: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Active recruiting
The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.